Table 3.
Prosigna-trained results stratified by other test results, trinary classification.
| Prosigna-trained first | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prosigna-trained low risk | Prosigna-trained intermediate risk | Prosigna-trained high risk | |||||||||||||||||||||||||
| HR (95% CI) | DMFS (95% CI) | P* (N) | HR (95% CI) | DMFS (95% CI) | P (N) | HR (95% CI) | DMFS (95% CI) | P (N) | |||||||||||||||||||
| All cases | REF |
92.1 (89.8–94.0) |
<0.001 (826) |
1.97 (1.44–2.69) |
84.9 (82.3–87.1) |
<0.001 (1155) |
4.24 (3.18–5.66) |
71.4 (68.6–74.1) |
<0.001 (1303) |
||||||||||||||||||
| N−Ch− | REF |
96.7 (92.0–98.7) |
<0.001 (220) |
3.06 (1.16–8.08) |
91.0 (86.4–94.1) |
0.024 (321) |
7.76 (3.13–19.2) |
80.5 (75.7–84.3) |
<0.001 (429) |
||||||||||||||||||
| N+Ch− | REF |
90.1 (85.8–93.2) |
<0.001 (318) |
1.35 (0.85–2.15) |
86.2 (82.1–89.4) |
0.204 (476) |
4.43 (2.93–6.69) |
63.9 (58.6–68.7) |
<0.001 (453) |
||||||||||||||||||
| Ch+ | REF |
90.9 (86.3–94.0) |
<0.001 (287) |
2.64 (1.63–4.27) |
77.8 (72.5–82.2) |
<0.001 (356) |
3.74 (2.37–5.92) |
70.4 (65.2–74.9) |
<0.001 (417) |
||||||||||||||||||
| Oncotype-trained Low | Oncotype-trained Int | Oncotype-trained high | Oncotype-trained low | Oncotype-trained Int | Oncotype-trained high | Oncotype-trained low | Oncotype-trained Int | Oncotype-trained high | |||||||||||||||||||
| HR | DMFS | P* | HR | DMFS | P | HR | DMFS | P | HR | DMFS | P* | HR | DMFS | P | HR | DMFS | P | HR | DMFS | P* | HR | DMFS | P | HR | DMFS | P | |
| All cases | REF |
92.2 (89.5–94.2) |
0.737 (643) |
1.07 (0.56–2.03) |
91.5 (85.2–95.2) |
0.835 (174) |
NA | 100 |
NA (9) |
REF |
88.5 (85.3–91.0) |
<0.001 (685) |
1.86 (1.31-2.66) |
81.4 (76.5-85.4) |
0.001 (381) |
3.08 (1.89-5.01) |
72.6 (61.0-81.3) |
<0.001 (89) |
REF |
75.4 (68.3–81.1) |
<0.001 (279) |
1.27 (0.92–1.75) |
73.3 (69.2–77.0) |
0.148 (618) |
1.78 (1.28–2.47) |
65.7 (60.4–70.5) |
0.001 (406) |
| N−Ch− | REF |
97.1 (92.5–98.9) |
0.955 (174) |
1.03 (0.12–9.26) |
94.1 (65.0–99.1) |
0.976 (43) |
NA | 100 |
NA (3) |
REF |
92.4 (86.3-95.8) |
0.395 (189) |
1.69 (0.72-3.97) |
87.5 (77.3-93.4) |
0.232 (106) |
0.69 (0.09-5.34) |
94.7 (68.1-99.2) |
0.721 (26) |
REF |
83.8 (70.1-91.6) |
0.012 (95) |
1.26 (0.61-2.59) |
83.7 (77.1-91.6) |
0.535 (200) |
2.35 (1.15-4.78) |
72.8 (63.4-80.2) |
0.019 (134) |
| N+Ch− | REF |
89.3 (84.4–92.7) |
0.701 (263) |
0.62 (0.19–2.07) |
94.3 (83.4–98.1) |
0.441 (54) |
NA | 100 |
NA (1) |
REF |
89.1 (84.1-92.5) |
0.008 (309) |
1.93 (1.09-3.43) |
81.8 (73.1-87.9) |
0.025 (142) |
3.21 (1.32-7.80) |
74.5 (51.7–87.7) |
0.010 (25) |
REF |
70.3 (58.1–79.6) |
<0.001 (111) |
1.29 (0.80–2.09) |
69.0 (61.4–75.4) |
0.291 (207) |
2.27 (1.41–3.65) |
51.1 (41.5–59.8) |
0.001 (135) |
| Ch+ | REF |
91.9 (86.5–95.2) |
0.552 (205) |
1.51 (0.63–3.60) |
87.9 (76.9–93.9) |
0.353 (77) |
NA | 100 |
NA (5) |
REF |
83.4 (76.0-88.7) |
<0.001 (185) |
1.72 (1.01-2.94) |
76.2 (67.4-83.0) |
0.046 (133) |
3.47 (1.83-6.58) |
56.4 (37.0–71.9) |
<0.001 (38) |
REF |
71.7 (57.0–82.1) |
0.644 (73) |
1.24 (0.71–2.15) |
67.4 (59.7–74.0) |
0.445 (208) |
1.06 (0.58–1.92) |
73.8 (65.1–80.7) |
0.854 (136) |
| Mammaprint-trained low | Mammaprint trained high | Mammaprint-trained low | Mammaprint-trained high | Mammaprint-trained low | Mammaprint-trained high | ||||||||||||||||||||||
| HR | DMFS | P* | HR | DMFS | P | HR | DMFS | P* | HR | DMFS | P | HR | DMFS | P* | HR | DMFS | P | ||||||||||
| All cases | REF |
92.2 (89.8–94.0) |
0.753 (814) |
1.37 (0.19–9.92) |
90.0 (47.3–98.5) |
0.754 (12) |
REF |
86.1 (83.3–88.5) |
0.005 (944) |
1.69 (1.16–2.44) |
79.4 (72.6–84.7) |
0.006 (211) |
REF |
78.1 (73.0–82.3) |
<0.001 (422) |
1.64 (1.26–2.12) |
68.4 (64.9–71.7) |
<0.001 (881) |
|||||||||
| N−Ch− | REF |
96.6 (91.8–98.6) |
0.763 (217) |
NA | 100 |
NA (3) |
REF |
93.1 (88.1–96.0) |
0.031 (249) |
2.47 (1.06–5.79) |
83.8 (70.2–91.5) |
0.037 (72) |
REF |
89.6 (80.6–94.5) |
0.002 (133) |
2.78 (1.43–5.44) |
76.5 (70.6–81.4) |
0.003 (296) |
|||||||||
| N+Ch− | REF |
90.0 (85.7–93.1) |
0.601 (315) |
NA | 100 |
NA (3) |
REF |
86.6 (82.2–90.0) |
0.371 (415) |
1.38 (0.68–2.84) |
83.6 (70.7–91.1) |
0.373 (61) |
REF |
75.7 (66.8–82.5) |
<0.001 (166) |
2.09 (1.41–3.10) |
57.4 (50.8–63.5) |
<0.001 (287) |
|||||||||
| Ch+ | REF |
91.1 (86.5–94.2) |
0.280 (281) |
2.88 (0.39–21.4) |
75.0 (12.8–96.1) |
0.302 (6) |
REF |
79.3 (73.3–84.2) |
0.066 (278) |
1.62 (0.96-2.73) |
72.7 (60.8-81.5) |
0.069 (78) |
REF |
69.0 (58.8-77.2) |
0.948 (122) |
0.99 (0.65-1.49) |
70.9 (64.7-76.2) |
0.948 (295) |
|||||||||
HR = Hazard ratio. 95%CI = 95% confidence interval. P* = p value of log-rank test to compare survival distributions. REF = reference group. P = p value of Wald test for comparison versus reference (low risk) group. DMFS = distant metastasis free survival at 10 years (see text). (N) = number of cases in subgroups. All cases = all ER+ve/HER2-ve cases. N−Ch− = Node negative cases treated without chemotherapy. N+Ch− = Node positive cases treated without chemotherapy. Ch+= cases treated with chemotherapy (node negative and node positive combined). Int = intermediate.